GlassScriptPhysician profile
Anthony R Cucci
NPI 1629364690
$263,652.42
in general payments reported to CMS, 2019-2025
9 companies · $79K in 2025
The $79K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $120 · 2021: $1,499 · 2022: $23K · 2023: $63K · 2024: $97K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $171K · Consulting Fee: $33K · Travel and Lodging: $27K · Food and Beverage: $8,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $170,940.00 |
| Consulting Fee | $32,851.85 |
| Travel and Lodging | $26,802.32 |
| Food and Beverage | $8,489.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $257,151.72 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Chiesi USA, INC. | $5,266.72 | 2025 | |
| Insmed, INC. | $789.39 | 2019-2023 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $275.79 | 2021-2024 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $52.96 | 2024-2025 | Winrevair |
| Abiomed | $43.60 | 2025 | |
| Glaxosmithkline, LLC. | $30.53 | 2025 | Nucala |
| Liquidia Technologies, INC. | $27.07 | 2025 | Yutrepia |
| Astrazeneca Pharmaceuticals LP | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Cucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.